- Home
- JWEL vs NCNA Comparison
JWEL vs NCNA Comparison
Compare JWEL & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- NCNA
- Stock Information
- Founded
- JWEL 2012
- NCNA 1997
- Country
- JWEL China
- NCNA United Kingdom
- Employees
- JWEL N/A
- NCNA N/A
- Industry
- JWEL Other Consumer Services
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- NCNA Health Care
- Exchange
- JWEL Nasdaq
- NCNA Nasdaq
- Market Cap
- JWEL 4.1M
- NCNA 4.4M
- IPO Year
- JWEL 2021
- NCNA 2017
- Fundamental
- Price
- JWEL $2.43
- NCNA $1.27
- Analyst Decision
- JWEL
- NCNA Buy
- Analyst Count
- JWEL 0
- NCNA 2
- Target Price
- JWEL N/A
- NCNA $25.00
- AVG Volume (30 Days)
- JWEL 881.8K
- NCNA 99.0K
- Earning Date
- JWEL 12-27-2024
- NCNA 11-25-2024
- Dividend Yield
- JWEL N/A
- NCNA N/A
- EPS Growth
- JWEL N/A
- NCNA N/A
- EPS
- JWEL N/A
- NCNA N/A
- Revenue
- JWEL $160,009,293.00
- NCNA N/A
- Revenue This Year
- JWEL N/A
- NCNA N/A
- Revenue Next Year
- JWEL N/A
- NCNA N/A
- P/E Ratio
- JWEL N/A
- NCNA N/A
- Revenue Growth
- JWEL N/A
- NCNA N/A
- 52 Week Low
- JWEL $1.00
- NCNA $1.20
- 52 Week High
- JWEL $3.71
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- JWEL 44.78
- NCNA 38.62
- Support Level
- JWEL $2.45
- NCNA $1.23
- Resistance Level
- JWEL $3.13
- NCNA $1.39
- Average True Range (ATR)
- JWEL 0.36
- NCNA 0.06
- MACD
- JWEL -0.11
- NCNA 0.03
- Stochastic Oscillator
- JWEL 3.67
- NCNA 37.05
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.